• Publications
  • Influence
Calciphylaxis: a still unmet challenge.
INTRODUCTION Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a rare disease most frequently occurring in patients with advanced chronic kidney disease (CKD). The clinicalExpand
  • 79
  • 10
Pathogenesis of vascular calcification in chronic kidney disease.
Pathogenesis of vascular calcification in chronic kidney disease. Background. Hyperphosphatemia and hypercalcemia are independent risk factors for higher incidence of cardiovascular events inExpand
  • 222
  • 9
  • PDF
Vascular calcification in chronic kidney disease: different bricks in the wall?
A high prevalence of vascular calcification (VC) and a high incidence of cardiovascular events are two key complications of chronic kidney disease. Since most observational studies found a positiveExpand
  • 111
  • 7
Cardiovascular disease in dialysis patients
Abstract Cardiovascular disease (CVD) is a highly common complication and the first cause of death in patients with end-stage renal disease (ESRD) on haemodialysis (HD). In this population, mortalityExpand
  • 87
  • 7
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D
Background: A high prevalence of bone demineralization occurs in people living with HIV/AIDS. The contribution of HIV itself and its treatment is still unclear. Protease inhibitors (PIs) are potentExpand
  • 208
  • 5
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
Background Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titratedExpand
  • 89
  • 5
  • PDF
Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
BACKGROUND The control of parathyroid hyperplasia and high circulating parathyroid hormone (PTH) levels is crucial in preventing secondary hyperparathyroidism (SH) in renal failure. Parathyroid glandExpand
  • 53
  • 5
  • PDF
New insights into the FGF23-Klotho axis.
Abnormal mineral metabolism is a hallmark in patients with advanced chronic kidney disease (CKD). Hyperphosphatemia, and the homeostatic mechanisms controlling phosphate metabolism, have receivedExpand
  • 64
  • 5
Management of calcium refilling post-parathyroidectomy in end-stage renal disease.
BACKGROUND Management of post-parathyroidectomy hypocalcemia in dialysis patients is not well defined. We reviewed published approaches to treatment in an effort to define a clinical algorithm forExpand
  • 38
  • 5
  • PDF
Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
According to the recent definition proposed by the Consensus conference on Acute Dialysis Quality Initiative Group, the term cardio-renal syndrome (CRS) has been used to define different clinicalExpand
  • 45
  • 5
...
1
2
3
4
5
...